Conatus Pharmaceuticals Inc. (CNAT) Is Surging On Novartis Agreement

Conatus Pharmaceuticals Inc. (CNAT) announced after the bell Monday that it has entered into an exclusive option, collaboration and license agreement with Novartis to develop and commercialize emricasan.

from RTT - Hot Stocks http://ift.tt/2hDN8js
via IFTTT